Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:CING NASDAQ:IBIO NASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ACINGCingulate$4.98-5.1%$6.48$3.20▼$11.89$64.32M-0.81463,495 shs435,111 shsIBIOiBio$1.61+1.9%$2.18$0.56▼$3.82$57.11M1.23932,595 shs795,254 shsOKYOOKYO Pharma$1.60-4.8%$1.63$1.32▼$3.35$68.13M-0.0184,930 shs33,199 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%CINGCingulate-7.26%+6.41%-18.89%-20.32%+22.36%IBIOiBio+1.26%-1.23%-18.69%-26.82%+160,999,900.00%OKYOOKYO Pharma-3.61%+1.27%-4.76%-18.37%+8.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ACINGCingulate$4.98-5.1%$6.48$3.20▼$11.89$64.32M-0.81463,495 shs435,111 shsIBIOiBio$1.61+1.9%$2.18$0.56▼$3.82$57.11M1.23932,595 shs795,254 shsOKYOOKYO Pharma$1.60-4.8%$1.63$1.32▼$3.35$68.13M-0.0184,930 shs33,199 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%CINGCingulate-7.26%+6.41%-18.89%-20.32%+22.36%IBIOiBio+1.26%-1.23%-18.69%-26.82%+160,999,900.00%OKYOOKYO Pharma-3.61%+1.27%-4.76%-18.37%+8.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.75Reduce$1.251,113.59% UpsideCINGCingulate 2.33Hold$34.50592.77% UpsideIBIOiBio 3.17Buy$4.75195.03% UpsideOKYOOKYO Pharma 2.40Hold$6.33295.83% UpsideCurrent Analyst Ratings BreakdownLatest APLT, OKYO, CING, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.004/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $55.003/27/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.003/18/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/3/2026IBIOiBio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/2/2026IBIOiBio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy2/20/2026OKYOOKYO Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.002/20/2026OKYOOKYO Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21CINGCingulateN/AN/AN/AN/A$0.31 per shareN/AIBIOiBio$400K145.46N/AN/A$0.90 per share1.79OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/ACINGCingulate-$22.45M-$4.32N/AN/AN/AN/A-509.72%-172.37%5/14/2026 (Estimated)IBIOiBio-$18.38M-$1.00N/AN/AN/AN/A-71.26%-57.92%N/AOKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A6/3/2026 (Estimated)Latest APLT, OKYO, CING, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CINGCingulate-$0.53N/AN/AN/AN/AN/A3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/A2/10/2026Q2 2026IBIOiBio-$0.08-$0.09-$0.01-$0.09$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96CINGCingulate0.461.161.16IBIOiBioN/A9.049.04OKYOOKYO PharmaN/A0.58N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CINGCingulate41.31%IBIOiBio7.90%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%CINGCingulate4.33%IBIOiBio2.75%OKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableCINGCingulate2012.25 million11.72 millionNot OptionableIBIOiBio10036.14 million35.15 millionN/AOKYOOKYO Pharma740.56 million24.15 millionNot OptionableAPLT, OKYO, CING, and IBIO HeadlinesRecent News About These CompaniesOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts3 hours ago | marketbeat.comOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in AprilApril 29, 2026 | marketbeat.comOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayApril 29, 2026 | globenewswire.comOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in MarchApril 15, 2026 | marketbeat.comOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by BrokeragesApril 11, 2026 | marketbeat.comOKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026April 7, 2026 | finance.yahoo.comOKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentationApril 7, 2026 | proactiveinvestors.comOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingApril 7, 2026 | globenewswire.comMost and least shorted healthcare stocks with up to $2B market cap in MarchApril 3, 2026 | msn.comOKYO reports improved quality of life outcomes with urcosimod in phase 2a NCP trialMarch 20, 2026 | ophthalmologytimes.comOOKYO Pharma Announces Chairman and Founder Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Director Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Chief Development Officer and Director Acquires SharesMarch 19, 2026 | globenewswire.comFTSE 100 Live: Stocks expected to slump as oil prices soar on Iran counterattacksMarch 19, 2026 | proactiveinvestors.comOKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trialMarch 18, 2026 | proactiveinvestors.comOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainMarch 18, 2026 | globenewswire.comNasdaq, Dow Jones start the week lower as Trump resets tariffsFebruary 23, 2026 | finance.yahoo.comOKYO Pharma to present first-in-human urcosimod data at ARVO 2026February 23, 2026 | proactiveinvestors.co.ukOKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressFebruary 23, 2026 | globenewswire.comOKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal painFebruary 17, 2026 | proactiveinvestors.comOKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal painFebruary 17, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Bottom Is in for Micron Stock: 3 Signals to Buy NowBy Thomas Hughes | April 8, 2026Microsoft’s Copilot Problem Isn’t What You ThinkBy Chris Markoch | April 12, 2026The $600 Billion Buy Signal For SanDisk Stock By Jeffrey Neal Johnson | April 15, 2026GPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026PepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 2026APLT, OKYO, CING, and IBIO Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 05/4/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cingulate NASDAQ:CING$4.98 -0.27 (-5.14%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$5.06 +0.08 (+1.61%) As of 06:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.iBio NASDAQ:IBIO$1.61 +0.03 (+1.90%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.61 0.00 (0.00%) As of 05:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.OKYO Pharma NASDAQ:OKYO$1.60 -0.08 (-4.76%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.65 +0.05 (+3.12%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
